Abstract 15267: Efficacy and Safety of Combination Therapy with GLP-1 and SGLT2 Inhibitors versus GLP-1 Monotherapy in Patients with Type 2 Diabetes and Heart Failure with Preserved Ejection Fraction (HFpEF)
Background: According to the European Society of Cardiology (ESC) guidelines, both GLP-1 receptor agonists and SGLT2 inhibitors have documented cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM), with SGLT2 inhibitors particularly recommended to reduce heart failure hospitalizations. However, r...